Pfizer-Backed DEM Bio Launches to Leverage CRISPR in Immuno-Oncology

DEM BioPharma, backed by an impressive list of investors, debuted Thursday with $70 million that will assist in its efforts to treat cancer with an approach that leverages CRISPR screening and macrophage biology in immuno-oncology.